ICON Public (NASDAQ:ICLR) Posts Earnings Results, Beats Estimates By $0.01 EPS

ICON Public (NASDAQ:ICLR) posted its earnings results on Wednesday. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01, Zacks reports. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.79% and a net margin of 9.56%.

ICON Public Price Performance

ICLR stock traded up $0.81 during midday trading on Friday, reaching $202.65. The stock had a trading volume of 411,634 shares, compared to its average volume of 960,870. The company’s fifty day simple moving average is $203.04 and its 200 day simple moving average is $246.13. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a market cap of $16.72 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 1.76 and a beta of 1.19. ICON Public has a 52-week low of $181.51 and a 52-week high of $347.72.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ICLR shares. Truist Financial decreased their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. TD Cowen decreased their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Robert W. Baird decreased their price target on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Finally, Barclays decreased their price objective on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research report on Friday. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and an average target price of $281.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.